BR112019011713A2 - anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma - Google Patents

anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma

Info

Publication number
BR112019011713A2
BR112019011713A2 BR112019011713-0A BR112019011713A BR112019011713A2 BR 112019011713 A2 BR112019011713 A2 BR 112019011713A2 BR 112019011713 A BR112019011713 A BR 112019011713A BR 112019011713 A2 BR112019011713 A2 BR 112019011713A2
Authority
BR
Brazil
Prior art keywords
adm
congestion
intervention
therapy
framework
Prior art date
Application number
BR112019011713-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Voors Adriaan
Original Assignee
Adrenomed Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16206305.1A external-priority patent/EP3339324A1/en
Application filed by Adrenomed Ag filed Critical Adrenomed Ag
Publication of BR112019011713A2 publication Critical patent/BR112019011713A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112019011713-0A 2016-12-16 2017-12-18 anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma BR112019011713A2 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP16204847 2016-12-16
EP16204847.4 2016-12-16
EP16206305.1A EP3339324A1 (en) 2016-12-22 2016-12-22 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof
EP16206305.1 2016-12-22
EP17197176 2017-10-18
EP17197176.5 2017-10-18
PCT/EP2017/083311 WO2018109228A1 (en) 2016-12-16 2017-12-18 Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof

Publications (1)

Publication Number Publication Date
BR112019011713A2 true BR112019011713A2 (pt) 2019-10-15

Family

ID=61148166

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112019011713-0A BR112019011713A2 (pt) 2016-12-16 2017-12-18 anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma

Country Status (13)

Country Link
US (2) US20200299372A1 (https=)
EP (1) EP3555130A1 (https=)
JP (3) JP7727371B2 (https=)
KR (3) KR20240033285A (https=)
CN (2) CN110167962B (https=)
AU (2) AU2017375049B2 (https=)
BR (1) BR112019011713A2 (https=)
CA (1) CA3046850A1 (https=)
IL (2) IL322765A (https=)
MX (1) MX2019007107A (https=)
MY (1) MY208219A (https=)
RU (1) RU2762059C2 (https=)
WO (1) WO2018109228A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3687567T3 (fi) * 2017-09-25 2025-01-08 Adrenomed Ag Adrenomedulliinin (adm) vasta-ainetta sitova aine käytettäväksi sairauden oireiden hoidossa tai ehkäisyssä
EP3871689A1 (en) * 2020-02-26 2021-09-01 sphingotec GmbH Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c
CA3168978A1 (en) * 2020-02-27 2021-09-02 Andreas Bergmann Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock
US20210285949A1 (en) * 2020-03-16 2021-09-16 Sphingotec Gmbh Pro-adrenomedullin or fragment thereof in patients infected with corona virus and treatments with binder against adrenomedullin
CA3254142A1 (en) 2022-03-15 2023-09-21 Adrenomed Ag STABLE AQUEOUS FORMULATION OF AN ANTI-ADRENOMEDULLIN (ADM) ANTIBODY OR AN ANTI-ADM ANTIBODY FRAGMENT

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
AU634716B2 (en) 1988-08-01 1993-03-04 Ciba Corning Diagnostics Corp. Method for detection of an analyte using acridinium esters and liposomes
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2124967C (en) 1991-12-17 2008-04-08 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
JP2774769B2 (ja) 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
RU2004109222A (ru) 2001-08-30 2005-10-20 Байорексис Фармасьютикал Корпорейшн (Us) Слитые белки модифицированного трансферрина
WO2003103475A2 (en) 2002-06-07 2003-12-18 Dyax Corp. Prevention and reduction of blood loss
DE10316583A1 (de) 2003-04-10 2004-10-28 B.R.A.H.M.S Aktiengesellschaft Bestimmung eines midregionalen Proadrenomedullin-Teilpeptids in biologischen Flüssigkeiten zu diagnostischen Zwecken, sowie Immunoassays für die Durchführung einer solchen Bestimmung
EP1620734A1 (en) 2003-04-25 2006-02-01 Genova Ltd. Secreted polypeptide species reduced cardiovascular disorders
WO2005040229A2 (en) 2003-10-24 2005-05-06 Avidia, Inc. Ldl receptor class a and egf domain monomers and multimers
US20100028995A1 (en) 2004-02-23 2010-02-04 Anaphore, Inc. Tetranectin Trimerizing Polypeptides
US20070280886A1 (en) 2004-09-09 2007-12-06 Bayer Healthcare Ag Diagnostics and Therapeutics for Diseases Associated with Adrenomedullin Receptor (Amdr)
US8278262B2 (en) 2004-09-21 2012-10-02 Biontech Ag Use of microproteins as tryptase inhibitors
DK2231860T3 (da) 2007-12-19 2011-12-05 Affibody Ab Polypeptid afledt protein A og i stand til at binde PDGF
EP2324059A4 (en) * 2008-07-01 2012-12-05 Cephalon Australia Vic Pty Ltd THERAPEUTIC ANTI-PAMP ANTIBODIES
EP3785735A1 (en) 2008-11-03 2021-03-03 Molecular Partners AG Binding proteins inhibiting the vegf-a receptor interaction
MX2012002428A (es) 2009-08-27 2012-09-12 Covagen Ag Compuestos de union il-17 y usos medicos de los mismos.
AU2010332932B2 (en) 2009-12-14 2013-01-17 Navigo Proteins Gmbh Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin
RU2569745C2 (ru) 2010-06-08 2015-11-27 Пиерис АГ Мутеины липокалина слезы, связывающие альфа il-4 r
JP5827323B2 (ja) * 2010-06-18 2015-12-02 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング ガン罹患の予測のためのバイオマーカー
DK2780717T3 (en) * 2011-11-16 2017-02-13 Sphingotec Gmbh ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN
PL2594588T3 (pl) * 2011-11-16 2014-11-28 Adrenomed Ag Przeciwciało przeciwko adrenomedulinie (ADM) lub fragment przeciwciała anty-ADM lub szkielet białkowy niestanowiący Ig anty-ADM do zastosowania w terapii
EP2780370B1 (en) * 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
DK2780371T3 (en) * 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
EP4086283A1 (en) * 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
SG11201402362VA (en) * 2011-11-16 2014-06-27 Adrenomed Ag Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition

Also Published As

Publication number Publication date
CN118767128A (zh) 2024-10-15
JP2023052614A (ja) 2023-04-11
JP7727371B2 (ja) 2025-08-21
CN110167962A (zh) 2019-08-23
MX2019007107A (es) 2019-10-21
EP3555130A1 (en) 2019-10-23
US20220041703A1 (en) 2022-02-10
IL267282A (en) 2019-08-29
AU2017375049A1 (en) 2019-06-13
RU2019122135A (ru) 2021-01-18
KR20240033285A (ko) 2024-03-12
IL322765A (en) 2025-10-01
KR20250084231A (ko) 2025-06-10
CA3046850A1 (en) 2018-06-21
MY208219A (en) 2025-04-24
WO2018109228A1 (en) 2018-06-21
AU2017375049B2 (en) 2025-01-30
US20200299372A1 (en) 2020-09-24
JP2024170454A (ja) 2024-12-10
RU2021135712A (ru) 2021-12-30
CN110167962B (zh) 2024-06-07
KR20190120174A (ko) 2019-10-23
RU2762059C2 (ru) 2021-12-15
AU2025202983A1 (en) 2025-05-22
JP2020503013A (ja) 2020-01-30
RU2019122135A3 (https=) 2021-02-10

Similar Documents

Publication Publication Date Title
BR112019011713A2 (pt) anticorpo anti-adrenomedulina (adm) ou fragmento de anticorpo anti-adm ou arcabouço anti-adm não ig para uso na intervenção e terapia da congestão em um paciente com necessidade da mesma
BR112016026993A2 (pt) combinação de um anticorpo anti-ccr4 e um agonista 4-1bb para tratar câncer
BR112018014016A2 (pt) combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer
BR112017000664A2 (pt) anticorpo anti-pd-1 e seu uso
MX2021000538A (es) Uso de sobetirome en el tratamiento de enfermedades de mielinizacion.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
BR112016025470A2 (pt) ?hdl terapêutico?
DOP2016000133A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
SV2017005389A (es) Terapia combinada
BR112016005816A2 (pt) Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
DK3740504T3 (da) CD70 kombinationsterapi
BR112017001162A2 (pt) métodos para tratar paramixovírus
MX2015016627A (es) Vacuna para la malaria.
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
EP3834750C0 (en) MEDICAL INSTRUMENT
BR112017007414A2 (pt) combinações compreendendo siponimod e laquinimod para o tratamento de esclerose múltipla
BR112016017620A2 (pt) Composto esteroidal para uso no tratamento da encefalopatia hepática
EP3643254A4 (en) Clipping tool
BR112018071547A2 (pt) acetil-leucina ou um sal farmaceuticamente aceitável desta
EP3747479A4 (en) MEDICAL INSTRUMENT
BR112018001907A2 (pt) uso de anticorpos anti-cd40 para o tratamento de nefrite lúpica
BR112016003030A2 (pt) anticorpos iib do receptor anti-fc-gama e uso dos mesmos
EP3834747C0 (en) MEDICAL INSTRUMENT

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]